15 November 2019

Yogesh Puri, Vasanthakumar Gunasekaran, Shiva Kumar Palanisamy, Babu Elangovan, Pradeep Krishna, Balaji Balasubramanian, Anjana Ananth, Mettu Srinivas Reddy, Mohamed Rela – 14 November 2019

Josh Levitsky, Bryna E. Burrell, Sai Kanaparthi, Laurence A. Turka, Sunil Kurian, Alberto Sanchez‐Fueyo, Juan J. Lozano, Anthony Demetris, Andrew Lesniak, Allan D. Kirk, Linda Stempora, Guang‐Yu Yang, James M. Mathew – 13 November 2019

Tomasz Kostrzewski, Paloma Maraver, Larissa Ouro‐Gnao, Ana Levi, Sophie Snow, Alina Miedzik, Krista Rombouts, David Hughes – 13 November 2019 – Nonalcoholic steatohepatitis (NASH) is the most severe form of nonalcoholic fatty liver disease (NAFLD), which to date has no approved drug treatments. There is an urgent need for better understanding of the genetic and molecular pathways that underlie NAFLD/NASH, and currently available preclinical models, be they in vivo or in vitro, do not fully represent key aspects of the human disease state.

At the 2019 Leon Schiff State-of-the-Art Lecture, our selected speaker will provide a thorough overview of the advances in knowledge of the pathogenesis of hepatocellular carcinoma (HCC). The lecture will explore current data on evidence-based treatment of this disease, including novel molecular therapies and advances in precision oncology.

Review key highlights from all the exciting clinical research presented at The Liver Meeting® 2019.

Review a condensed summary of the clinical research highlights from The Liver Meeting.

Digest a debrief of the newest data on the treatment of viral hepatitis presented at The Liver Meeting.

Richard Curnock, Nigel D. Heaton, Hector Vilca‐Melendez, Anil Dhawan, Nedim Hadzic, Roshni Vara – 12 November 2019 – Liver transplantation (LT) for patients with propionic acidemia (PA) is an emerging therapeutic option. We present a retrospective review of patients with PA who underwent LT at a tertiary liver center between 1995 and 2015. A total of 14 children were identified (8 males) with median age at initial presentation of 3 days (range, 0‐77 days).

Markus Cornberg, Anna Suk‐Fong Lok, Norah A. Terrault, Fabien Zoulim, the 2019 EASL‐AASLD HBV Treatment Endpoints Conference Faculty – 12 November 2019 – Representatives from academia, industry, regulatory agencies, and patient groups convened in March 2019 with the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to guide clinical trials aiming to “cure” HBV. Agreement among the conference participants was reached on some key points.